iTeos Therapeutics

$33.26 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About iTeos Therapeutics

iTeos Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovery and development of a differentiated immuno-oncology therapeutics for patients. The Company’s pipeline includes two clinical-stage programs EOS-448 and EOS-850. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system.

Stock Analysis

last close $33.26
1-mo return 19.4%
3-mo return 16.4%
avg daily vol. 306.3T
52-week high 47.61
52-week low 17.43
market cap. $1.2B
forward pe 8.7
annual div. -
roe 4.2%
ltg forecast -
dividend yield -
annual rev. $104M
inst own. 88.7%

Subscribe now for daily local and international financial news